Tagged with M

Minister of Higher Education and Research What has been the contribution of the LRU reform and specifically what has the Creation of Research Centers and Higher Education (PRES) done to establish universities back at the heart of the research strategy in France? French research produces excellent results, but still suffers from a lack of international visibility,…

Tecnoquímicas S.A.  Mr. Sardi, Exec-VP of Tecnoquímicas, the No. 1 producer and distributor of generic pharmaceutical drugs in Colombia, explains what makes Tecnoquímicas different from their contemporaries and how it grew with the changing landscape of the Colombian market to regain their No. 1 spot. What have been the constant factors that…

Endotis Pharma Endotis was incorporated in 2003 on the basis of a technology transfer from on a French public research institution. Can you elaborate on the origins? The group was founded from near scratch in 2003 based on a specific project that was unsuccessful at the time but rejuvenated in 2005 with…

Cegedim Deutschland GmbH You joined Cegedim in summer 2006 eleven months before its merger with Dendrite in 2007 that created the world leader in pharmaceutical CRM. How would you describe the integration process of both companies and what were the main synergies between Cegedim and Dendrite in the German context? Germany offered a…

Boehringer Ingelheim France There is a lot of change occurring in the French pharmaceutical industry at the moment and this is no different for Boehringer Ingelheim. Just last September you moved into these new facilities here at Paris Biopark. What does this express about the moves Boehringer Ingelheim is taking in France and…

Zuellig Pharma Asia Pacific You started the Chinese operations and have been working in the country for many years but recently moved up to running all operations in Asia Pacific. Are you still closely involved with what’s happening in China? I started the operations in China almost 16 years ago, and I started them…

Biogen Idec Germany Having experienced many years at big pharmaceutical companies, you recently moved into the booming biotech sector by joining Biogen Idec in 2007. What made you make such a decision? The growth potential of the biotech industry is incomparable to any other sector in the pharmaceutical industry, and the entire industry…

Dr. F. Köhler Chemie Your father was the founder of Dr. Franz Köhler Chemie – that carries his name – and was a very well respected doctor among the German medical and pharmaceutical community. What have been the main challenges you faced when taking over the company 25 years ago and becoming its General…

LEEM - Les Enterprises du Medicament What are the main tasks of the LEEM? The LEEM is the only professional organization representing the pharmaceutical industry in France. It includes almost all companies which seek to develop, manufacture and market drugs. Leem represents all components of the profession: international groups, medium-sized companies, an important fabric of small,…

GEMME Generic drugs were a very late arrival for the French market in comparison with other European markets and healthcare systems on a par with the French one. Today the gap has been narrowed very quickly as highlighted by public opinion and the fact everyone knows about generic drugs, but how…

LEEM - Les Enterprises du Medicament Throughout your prolific career in the pharmaceutical industry, what would you describe have been the major changes in the French pharmaceutical market and to what extent has France kept up? I think France has kept up with the world market albeit with some notable differences, namely in terms of our…

Hikma Pharma One of the biggest recent milestones for Hikma’s global operations must have been the acquisition of Ribosepharm and Thymoorgan in 2007. How successfully have the two companies integrated into the Hikma organisation, and how important are Hikma’s German operations for the company today? Hikma first established operations in Germany in…